Truist Securities Maintains Buy on Boston Scientific, Raises Price Target to $61
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Richard Newitter maintains a 'Buy' rating on Boston Scientific (NYSE:BSX) and raises the price target from $60 to $61.
July 19, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific's price target has been raised from $60 to $61 by Truist Securities, which maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by Truist Securities indicates a positive outlook for Boston Scientific. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100